ASH 2020

Last night we held a webinar  featuring a panel of experts discussing highlights in myeloma, lymphoma and leukaemia from ASH 2020, and their implications for clinical practice in Australia. If you didn't get the chance to join us, you can...

Last night we held a webinar  featuring a panel of experts discussing highlights in myeloma, lymphoma and leukaemia from ASH...

A highlight at the ASH Annual Meetings is the prestigious Ham-Wasserman lecture - named in honour of two distinguished past presidents of the Society. This year the 2020 Ham-Wasserman lecture was delivered by Australian Professor Andrew Roberts. Professor Roberts presented a history...

A highlight at the ASH Annual Meetings is the prestigious Ham-Wasserman lecture - named in honour of two distinguished past...

Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH...

Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple...